Antibe Therapeutics Inc. is a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology.

Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020.

In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine. On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug.

Traded as:           TSX: ATE

Industry:              Pharmaceuticals

Headquarters:   Toronto, Canada

Website:              www.antibethera.com